Inventor · disambiguated record
Guojun Lang
Also filed as: LANG GUOJUN
1 granted patent·9 pending applications·0 citations·filing 2020–2023
6Inventor score
Files withSANYOU BIOPHARMACEUTICALS CO LTD5ANHUI BIOX VISION BIOLOGICAL TECH CO LTD2CYTOLYNX THERAPEUTICS HONG KONG LTD1DRAGONBOAT BIOPHARMACEUTICAL SHANGHAI CO LTD1MINGHUI PHARMACEUTICAL SHANGHAI LTD1
Top patents by PatentIndex Score
10 records- 0148US2025026843A1Bispecific antibody against cd40 and cldn18.2 and application thereofANHUI BIOX VISION BIOLOGICAL TECH CO LTD·Filed 2022·Application pending·0 cites
- 0245US2024218071A1Anti-cd40 antibody and use thereofANHUI BIOX VISION BIOLOGICAL TECH CO LTD·Filed 2022·Application pending·0 cites
- 0344US2025257128A1Anti-CD47/Anti-CLDN18.2 Bispecific Antibody and Use ThereofDRAGONBOAT BIOPHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0442US2025043016A1Tnfr2 binding molecule and use thereofSANYOU BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0541US2025177546A1Ror1-targeted binding molecule and use thereofSANYOU BIOPHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0638US2023212294A1Anti-b7-h3 antibody and preparation therefor and use thereofMINGHUI PHARMACEUTICAL SHANGHAI LTD·Filed 2021·Application pending·0 cites
- 0736US12479922B2Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivityCYTOLYNX THERAPEUTICS HONG KONG LTD·Filed 2020·Granted Nov 25, 2025·0 cites·11 claims
- 0836US2024247060A1Cldn18.2 binding molecules and use thereofSANYOU BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0936US2023002494A1Pd-l1 binding moleculeSANYOU BIOPHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1029US2024092891A1Molecule Specifically Binding to CLDN18.2SANYOU BIOPHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guojun Lang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →